We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lowering Prices for Accelerated Approval Drugs Won’t Reduce Medicare Spending, Study Suggests
Lowering Prices for Accelerated Approval Drugs Won’t Reduce Medicare Spending, Study Suggests
Cutting prices for costly therapies approved under an accelerated pathway may not significantly reduce total prescription drug spending by Medicare, says a new study by researchers at Brigham and Women’s Hospital in Boston, Mass.